ArticleKidney international reports2025
The Bromodomain and Extraterminal Protein Inhibitor Apabetalone Ameliorates Kidney Injury in Diabetes by Regulating Cholesterol Accumulation and Modulating the Gut Microbiota.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cholesterol metabolism: molecular mechanisms, biological functions, diseases, and therapeutic targets.Molecular biomedicine · 2025Review
- Advancing Understanding of Mitochondrial Function in Diabetic Kidney Disease.Kidney international reports · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A US Food and Drug Administration-approved new bromodomain (BRD) and extraterminal (BET) bromine domain antagonist called apabetalone, which targets BRD4, has been shown to increase prebeta-1 high-density lipoprotein (HDL) particles, enhance apolipoprotein A-I in both humans and animals, and restore angiogenesis in experimental diabetes. Its action is not however fully known mechanistically. The objective of our research was to investigate the impact of apabetalone on renal damage linked to diabetic kidney disease (DKD). Methods: This research employed both pharmacological and genetic methods to examine the impact of apabetalone on db/db (BKS. Cg- Results: Here, significant reductions in blood creatinine, urea nitrogen, and urinary albumin-to-creatinine ratio (UACR) levels, serum triglycerides (TGs) and serum total cholesterol (TC), as well as ectopic lipid droplet formation in renal tissue, were seen in the db/db mice following apabetalone therapy. Analysis of the gut microbiota revealed changes in its composition. Significantly, the proportion of Conclusion: Therefore, we suggest that apabetalone showed significant antihyperlipidemic and antifibrotic effects, closely associated with alterations in the gut microbiota and cholesterol metabolism. The results of this investigation provide fresh perspectives on the processes that underlie apabetalone's effects in db/db mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.